Abstract. Abernethy malformation is a rare congenital malformation defined by an extrahepatic portosystemic shunt. The majority of affected patients are young (<18 years of age) and experience various symptoms, including vomiting, jaundice, dyspnea and coma. The current study presents a case of Abernethy malformation in an asymptomatic adult male patient. The patient exhibited congenital absence of the portal vein, congenital heart disease (postoperative ventricular septal defect status), and multiple liver lesions, confirmed to be focal nodular hyperplasia by biopsy. Ultrasonography and magnetic resonance imaging findings revealing the liver lesions, type II congenital absence of the portal vein and the portosystemic shunt are presented. In addition, the common clinical presentations, associated anomalies, diagnostic workup and treatment options of this disorder are investigated by reviewing 101 previously reported cases.

Introduction

Abernethy malformation is an extremely rare congenital vascular malformation that is characterized by the diversion of portal blood away from the liver (1). It frequently comprises a number of congenital anomalies of the liver, including congenital absence of the portal vein (CAPV), portosystemic shunt, and liver nodules, as well as congenital heart diseases such as atrial septal defect, ventricular septal defect (VSD) and patent ductus arteriosus (2).

The number of CAPV diagnoses has increased in recent years due to advances in imaging techniques (3,4). To the best of our knowledge, 101 cases of CAPV have been reported since the condition was first described in 1793 (1), and the majority of affected patients were <18 years of age and female (1,3-90). Almost all adult patients in the reported cases that have been reviewed in the present study were admitted to hospital with various symptoms including nausea, vomiting, fatigue, epigastric pain, asthenia, anorexia, jaundice and dyspnea (3-31).

In general, the treatment options for CAPV include surgical correction of shunts, liver nodule resectioning and liver transplantation. The outcome of CAPV in adults is good, and may be improved further by adopting appropriate treatment strategies.

The current study reports the case of multiple focal nodular hyperplasia (FNH) with CAPV in an asymptomatic adult male patient of postoperative VSD status. Written informed consent was obtained from the patient.

Case report

A 19-year-old male was admitted to the Endocrinology Department, Beijing Friendship Hospital (Beijing, China), due to a mildly elevated alanine transaminase level that had been incidentally identified during a routine health examination. No clinical evidence of encephalopathy or weight loss was observed. Physical examination revealed no abnormalities with the exception of mild jaundice and a diastolic murmur at the upper left sternal border. The patient's medical history included VSD and pulmonary valve stenosis, and the patient had undergone surgical VSD repair at 3 years of age. The mother also reported a mild viral infection (a cold) in her early pregnancy, which may have affected early fetal development.

Liver function testing showed an alanine transaminase level of 51 U/l (normal, 0-40 U/l), a γ-glutamyl transpeptidase level of 134 U/l (normal, 8-55 U/l), a total bilirubin level of 52.46 µmol/l (normal, 3.42-17.1 µmol/l) and an indirect bilirubin level of 36.83 µmol/l (normal, 0-12 µmol/l). Routine blood tests and a reticulocyte analysis revealed a white blood cell count of 6.8x10^9/l (normal range, 4.0-10.0x10^9/l), a neutrophil level of 3.6x10^9/l (normal range, 2.0-7.0x10^9/l), a red blood cell count of 5.5x10^12/l (normal range, 4.0-5.5x10^12/l), a hemoglobin level of 167 g/l (normal range, 120-160 g/l), platelet level of 226x10^9/l (normal range, 100-300x10^9/l) and reticulocyte level of 0.02x10^12/l (normal range, 0.01-0.09x10^12/l). No fragmented
red blood cells were identified in the peripheral blood. The coagulation profile was normal. Serological markers for ceruloplasmin and hepatitis A-E viruses as well as immunological markers were negative; α-fetoprotein was also negative.

Abdominal ultrasonography revealed a number of hypoechoic solid masses distributed in the right and left lobes of the liver, and an enlarged spleen. A splenorenal shunt was also detected. Magnetic resonance imaging was advised based on the abdominal ultrasound findings (Fig. 1). Magnetic resonance imaging confirmed the presence of a splenorenal shunt and multiple lesions with rich blood supplies. It also showed that the portal vein was slender with unclear branching. These findings led to the diagnosis of type II CAPV.

Percutaneous fine-needle aspiration biopsy of the liver nodules was subsequently performed (Fig. 2). Pathological examination revealed bile duct proliferation, hydropic degeneration of hepatocytes, hyperplasia of thick-walled arterioles and fibrosis in the portal area, but no intrahepatic cholestasis. The lesions were therefore confirmed to be FNH.

Electrocardiography revealed a right bundle branch block, and ultrasonic cardiography indicated congenital heart disease, postoperative VSD status, pulmonary valve stenosis and pulmonary regurgitation.

**Discussion**

The term CAPV was first coined by John Abernethy in 1793. Congenital extrahepatic portosystemic shunt is also known as Abernethy malformation in recognition of its initial identification (1). Complete portosystemic shunts that do not perfuse the liver via the portal vein are defined as type I, whereas partial shunts with a remaining degree of portal perfusion to the liver are defined as type II. Type I is further subclassified into types Ia and Ib according to the course of the splenic and mesenteric veins (32).

A number of patients with Abernethy malformation have been previously described (1,3-89). Among them, 66 were

| Group                  | Male   | Female  |
|------------------------|--------|---------|
| Case numbers, n        | ≥18    | <18     |
| Type: I/II/NA, n       | 7/2/0  | 15/3/8  |
| FNH/NRH, n             | 2/1    | 2/2     |
| Adenoma, n             | 0      | 0       |
| HCC, n                 | 2      | 4       |
| Hepatoblastoma, n      | 0      | 0       |
| Cirrhosis, n           | 0      | 1       |
| CHD, n                 | 2      | 6       |
| Kidney dysplasia, n    | 1      | 2       |
| Spleen dysplasia, n    | 0      | 1       |
| Dysostosis, n          | 0      | 2       |
| Arteries malformation, n | 0  | 1       |
| Bile duct dysplasia, n | 0      | 0       |
| Other coexistence congenital anomalies | 0 | Urethra,1 Nervous system,1 Caroll,1 Endocrine gland,1 Nervous system,1 Turner syndrome,2 Goldenhar syndrome,1 Down syndrome,1 |

NA, not applicable (not described in the reports); FNH, focal nodular hyperplasia; NRH, nodular regenerated hyperplasia; HCC, hepatocellular carcinoma; CHD, congenital heart disease.
female and 35 were male, with ages ranging from fetus to 61 years at the time of diagnosis. In total, 70 patients (69.30%) were <18 years of age, and <10% had type II malformations (45, 58, 75-77).

In the present case, imaging findings indicated that the portal vein had formed by the union of the splenic and superior mesenteric veins. These veins were present, but appeared slender and hypoperfused as a portion of the blood was being diverted into the inferior vena cava via a splenorenal shunt. Therefore, a diagnosis of type II Abernethy malformation was determined.

In addition to the absence of the portal vein, nodular liver lesions were observed in almost half of the reported cases (48.51%). The association between portal vein agenesis and nodular liver lesions is attributed to the absence of portal blood flow and compensatory increased hepatic arterial blood flow. Systemic shunting of the visceral venous return may lead to abnormal development, malfunction and regeneration of the liver, secondary to the absence of portal hepatotrophic factors, resulting in the development of hepatic lesions (87). The majority of these lesions were characterized as benign, such as FNH (36.73%). Other reported lesions included nodular regenerated hyperplasia (16.33%), hepatoblastoma (4.08%), hepatic adenoma (10.20%), hepatocellular carcinoma (26.53%) and cirrhosis (6.12%). In the current review, only a few patients with CAPV associated with FNH were male (8.16%; Table I).

The patient in the present case was in reasonable health following heart surgery and visited a doctor for the evaluation of an abnormal result obtained during a regular health examination. Although the patient felt no discomfort, the ultrasonography report indicated a more serious condition. Following a series of imaging examinations and a biopsy, malignant lesions were ruled out and it was concluded that the characteristic hepatic changes were secondary to the congenital malformation of the portal vein, and were associated with congenital heart disease.

Several known associations between primary liver disease and concomitant congenital cardiac defects have been identified (2). Congenital cardiac diseases including atrial septal defect, patent foramen ovale, VSD and patent ductus arteriosus are frequently observed concurrent with CAPV. Congenital stenosis of the aortic valve and pulmonary artery valve, observed in a number of patients with CAPV, can cause tricuspid regurgitation (36, 44, 90). However, it has also been hypothesized that systemic shunting of portal venous flow could adversely affect hepatic and cardiac development and function. Concomitant atrial and ventricular septal defects associated with CAPV may be attributed to a congenital adaptive change that occurs during development from the embryonic stage, which tends to compensate for the congestive effects of portal venous aplasia (2).

Another possible cause of vascular dysplasia is viral infection in early pregnancy, as occurred in the present case, where the patient's mother reported a mild viral infection (a cold) during early pregnancy. Embryologically, the portal vein originates from the paired vitelline veins. Between gestational weeks four and five, the paired vitelline veins form three anastomoses that, over the course of the first trimester, undergo selective involution to produce the portal vein (91). Aberrations in this process of involution may result in anatomical variations within the portal system; specifically, excessive involution may result in the absence of the portal vein. Almost simultaneously, a wall forms, separating the right and left ventricles. If the wall does not completely form, a hole remains. This hole is known as a VSD. Any abnormality in this process of involution may lead to VSD.
Among the reported cases, 46 cases associated with a variety of congenital anomalies were identified (92). In addition to the aforementioned congenital cardiac disease (16/46; 34.78%), other types of dysplasia involved the kidney (6/46; 13.04%), spleen (5/46; 10.87%), bone (4/46; 8.70%), arteries (3/46; 6.52%), bile duct (3/46; 6.52%), nervous system (2/46; 4.35%), urethra (1/46; 2.17%) and endocrine glands (1/46; 2.17%). In addition, a number of patients were affected by Turner syndrome (2/46; 4.35%), Caroli syndrome (1/46; 2.17%), Goldenhar syndrome (1/46; 2.17%) and Down syndrome (1/46; 2.17%; Table I).

The type of CAPV and simultaneous presence of congenital anomalies are the key factors in determining the severity of a given patient’s pathogenic condition and the course of the disease. Furthermore, the mode of management should be established on a case-by-case basis, according to the type or anatomy of the disease, in addition to the symptoms and clinical condition of the patient.

Treatments may include liver transplantation, balloon-occluded retrograde transvenous obliteration, embolization with metallic coils and surgical correction of shunts (93). In patients with type II malformations previously diagnosed with CAPV, occlusion of the shunt is indicated in cases with serious symptoms such as hepatic encephalopathy (43) or lateral bleeding. In the present case, the patient was asymptomatic, and the physical examination findings and laboratory test results appeared normal. Thus, we propose that close clinical, biochemical, and imaging follow-up must be performed and that interventional treatment should not be immediately conducted.

In conclusion, the diagnosis of Abernethy malformation and its associated anomalies is challenging. It is important not only to detect portal vein malformation, but also to identify other important associated anomalies, due to the variable clinical consequences. It appears that the long-term prognosis hinges on adequate control of the hepatic dysfunction and metabolic derangements; however, only longitudinal follow-up of these patients will provide further insight.

Acknowledgements

The authors would like to thank Dr HengChi Yu and Dr WeiJia Duan for their help with the document retrieval work. And we also thank Dr YaoEr Cheng for her valuable technical assistance in selecting the imaging figure.

References

1. J Abernethy, J Banks: Account of two instances of uncommon formation in the viscera of the human body. Philos Trans R Soc Lond 83: 59-66, 1793.
2. Asrani SK, Asrani NS, Freese DK, et al.: Congenital heart disease and the liver. Hepatology 56; 1160-1169, 2012.
3. Schaeffer DF, Lauri S, Jang HJ, John R and Adeyi OA: Abernethy malformation type II with nephrotic syndrome and other multisystemic presentation: an illustrative case for understanding pathogenesis of extraparenchymal shunt. Hum Pathol 44: 432-437, 2013.
4. Witjes CD, Ijzermans JN, Vonk Noordegraaf A and Tran TK: Successful liver transplantation with a small-for-size plantation in an adult with congenital absence of the portal vein. Abdom Imaging 29: 506-508, 2004.
5. Northrup M, Mendez-Castillo A, Sethi Y and Churchill R: Congenital absence of the portal vein associated with focal nodular hyperplasia in the liver in an adult woman: imaging and review of the literature. Abdom Imaging 29: 455-459, 2004.
6. Appel H, Loddenkemper C, Schirmacher P, et al.: Congenital absence of the portal vein with splenomegaly and hypersplenism in a young woman. Digestion 67: 105-110, 2003.
7. Wolfzeli M, Haagstra EB, Gouw AS, Slooff MJ and Porte RJ: Orthotopic liver transplantation for portosystemic encephalopathy in an adult with congenital absence of the portal vein. Liver Transpl 11: 1203-1207, 2005.
8. Cheung KM, Lee CY, Wong CT and Chan AK: Congenital absence of portal vein: differing as hepatopulmonary syndrome. J Paediatr Child Health 41: 72-75, 2005.
9. Tsuji K, Naoki K, Tachiyama Y, et al.: A case of congenital absence of the portal vein. Hepatol Res 31: 43-47, 2005.
10. Takagaki K, Kodaira M, Kuriyama S, et al.: Congenital absence of the portal vein complicating hepatic tumors. Intern Med 43: 194-198, 2004.
11. Kornprat P, Langner C, Fritz K and Mischinger HJ: Congenital absence of the portal vein in an adult woman: a case report. Wien Klin Wochenschr 117: 58-62, 2005.
12. Ohnishi Y, Ueda M, Doi H, et al.: Successful liver transplantation for congenital absence of the portal vein complicated by intrapulmonary shunt and brain abscess. J Pediatr Surg 40: E1-E3, 2005.
13. Takeichi T, Okajima H, Suda H, et al.: Living domino liver transplantation in an adult with congenital absence of portal vein. Liver Transpl 11: 1285-1288, 2005.
14. Oei M and Wessling J: Abernethy malformation - congenital aplasia of the portal vein a 29-year-old patient. RoFo 179: 167-169, 2007 (in German).
15. Collard B, Maleux G, Heye S, et al.: Value of carbon dioxide wedged venography and transvenous liver biopsy in the definitive diagnosis of Abernethy malformation. Abdom Imaging 31: 315-319, 2006.
16. Maekawa S, Suzuki T, Mori K, et al.: Congenital absence of the portal vein in an adult woman with liver tumor. NIH Shokakibyo Gakkai Zasshi 104: 1504-1511, 2007 (in Japanese).
17. Kong Y, Zhang H, Liu C, et al.: Abernethy malformation with multiple aneurysms: incidentally found in an adult woman with Caroli’s disease. Ann Hepatol 12: 327-331, 2013.
18. Matsuura T, Soejima Y and Taguchi T: Auxiliary partial orthotopic living donor liver transplantation with a small-for-size graft for congenital absence of the portal vein. Liver Transpl 16: 1457-1459, 2010.
19. Chandler TM, Heran MK, Chang SD, Parvez A and Harris AC: Multiple focal nodular hyperplasia lesions of the liver associated with congenital absence of the portal vein. Magn Reson Imaging 29: 881-886, 2011.
20. Banchetti F, Pellegriino L, Al-Ansari N, De Marco V, Scarpati P and Ialongo P: absence of the portal vein in a middle-aged man. Surg Radiol Anat 33: 369-372, 2011.
21. Caputo S and Mangiaglia CA: Severe portopulmonary hypertension associated with an unusual pattern of Abernethy malformation: three-dimensional computed tomography view. Echocardiography 29: E275-E277, 2012.
22. Scheuermann Ü, Fölts D and Otto G: Focal nodular hyperplasia proceeds hepatocellular carcinoma in an adult with congenital absence of the portal vein. Transpl Int 25: E67-E68, 2012.
23. Johnson R, Serban A, Popp R, et al.: Education and imaging: hepatobiliary and pancreatic: Abernethy malformation-congenital portocaval shunt. J Gastroenterol Hepatol 27: 1875, 2012.
50. Soejima Y, Taguchi T, Ogita K, Kohda E, Saeki M, Nakano M, Masaki H, Ogawa K, Nirasawa M: Congenital absence of the portal vein. Brain Dev 21: 425‑428, 1999.

51. Wakamoto H, Manabe K, Kobayashi H and Hayashi M: Subclinical portal‑systemic encephalopathy in a child with congenital absence of the portal vein. J Pediatr Gastroenterol Nutr 29: 77‑82, 1999.

52. Morgan G and Superina R: Congenital absence of the portal vein: a case report and MR demonstration. Pediatr Radiol 25: 52‑53, 1995.

53. Yamagishi H, Taniguchi I, Yamamoto T, et al: Analysis of intestinal flora of a patient with congenital absence of the portal vein. J Neonatal Perinatal Med 7: 89‑93, 1993.

54. Woodle ES, Thistlethwaite JR, Emond JC, Whitington PF, Vogelbaum MA, Zuidweg DS and Breslau CE: Successful hepatic transplantation in congenital absence of recipient portal vein. Surgery 107: 475‑479, 1990.

55. Nakasaka H, Tanaka Y, Ohta M, Kanemoto T, Mitomi T, Iwata Y and Ozawa A: Congenital absence of the portal vein. Ann Surg 219: 1009‑1012, 1994.

56. Usuki N and Miyamoto T: A case of congenital absence of the infrahepatic portal vein diagnosed by MR angiography. J Comput Assist Tomogr 22: 728‑729, 1998.

57. Kim SZ, Marz PL, Laor T, Teitelbaum J, Jonas MM and Levy HL: Elevated galactose in newborn screening due to congenital absence of the portal vein. Eur J Pediatr 157: 759‑761, 1998.

58. Guariso G, Fiorio S, Altavilla G, Favale MC, Dazzi P, Cultraro L and Piancastelli MG: The Abernethy malformation: a case report. J Pediatr Gastroenterol Nutr 28: 79‑83, 2002.

59. Howard ER and Davenport M: Congenital extrahepatic porto‑caval shunts ‑ the Abernethy malformation. J Pediatr Surg 32: 494‑497, 1997.

60. Massin M, Verloes A and Jamblin P: Cardiac anomalies associated with congenital absence of the portal vein. Cardiol Young 9: 522‑525, 1999.

61. Taoube KA, Alonso Calderon JL, Yandza T, Erturk S, Morotti RA, Killackey M, Shneider BL, Repucci A, Emre S and Thung SN: Hepatocellular carcinoma and congenital absence of the portal vein in a child receiving growth hormone therapy for Turner syndrome. Semin Liver Dis 27: 427‑431, 2007.

62. Emre S, Arnon R, Cohen E, Morotti RA, Vaysman D and Shneider BL: Resolution of hepato‑pulmonary syndrome after auxiliary partial orthotopic liver transplantation in Abernethy malformation. A case report. Liver Transpl 13: 1662‑1668, 2007.

63. Morikawa N, Honna T, Kuroda T, et al: Resolution of hepato‑pulmonary syndrome after ligation of a portosystemic shunt in a pediatric patient with an Abernethy malformation. J Pediatr Surg 43: E35‑E38, 2008.

64. Tsutsui M, Sugahara S, Motosusoe T, Wada H, Fukudai A, Umeda E and Kazama T: Anesthetic management of a child with Costello syndrome complicated by congenital absence of the portal vein. Brain Dev 22: 428‑429, 1999.

65. Kohda E, Saeki M, Nakano M, Masaki H, Ogawa K, IRSawa M and Hiramatsu K: Congenital absence of the portal vein in a boy. Pediatr Radiol 29: 235‑237, 1999.

66. Graziani L, Alberti D, Olivetti L, et al: Congenital absence of portal vein with nodular regenerative hyperplasia of the liver. Eur Radiol 10: 820‑825, 2000.

67. Andreani P, Srinivasan P, Ball CS, Heaton ND and Rela M: Congenital absence of the portal vein in liver transplantation for biliary atresia. Int J Surg Invest 2: 81‑84, 2000.

68. Alvarez AE, Ribeiro AF, Hessel G, Baracat J and Ribeiro JD: Abernethy malformation: one of the hepatic anomalies of portal‑pulmonary malformations. Pediatr Pulmonol 34: 599‑601, 2002.

69. Shinkai M, Ohhama Y, Nishi T, et al: Congenital absence of the portal vein and role of liver transplantation in children. J Pediatr Surg 36: 1026‑1031, 2001.

70. Kinjo T, Asahi K, Sunagawa H, Kinjo S and Muto Y: Congenital absence of the portal vein associated with focal nodular hyperplasia of the liver and congenital choledochal cyst: a case report. J Pediatr Surg 36: 622‑625, 2001.

71. Venkat-Raman N, Murphy KW, Ghaus K, Tesh TG, Higham JM and Carvalho AJ: Congenital absence of portal vein in the fetus: a case report. Ultrasound Obstet Gynecol 17: 71‑75, 2001.

72. Tanaka Y, Takayanagi M, Shiratori Y, et al: Congenital absence of portal vein with multiple hyperplastic nodular lesions in the liver. J Gastroenterol 38: 288‑294, 2003.

73. Sogabe M, Ojiya K, et al: Auxiliary partial orthotopic living donor liver transplantation for a child with congenital absence of the portal vein. Liver Transpl 12: 845‑849, 2006.
80. Asran MK, Loyer EM, Kaur H and Choi H: Case 177: Congenital absence of the portal vein with hepatic adenomatosis. Radiology 262: 364-367, 2012.

81. Chandrashekhara SH, Bhalla AS, Gupta AK, Vikash CS and Kabra SK: Abernethy malformation with portal vein aneurysm in a child. J Indian Assoc Pediatr Surg 16: 21-23, 2011.

82. Osorio MJ, Bonow A, Bond GJ, Rivera MR, Vaughan KG, Shah A and Shneider BL: Abernethy malformation complicated by hepatopulmonary syndrome and a liver mass successfully treated by liver transplantation. Pediatr Transplant 15: E149-E151, 2011.

83. Tannuri U, Galvão F, Leal AJ, Gibelli NE and Tannuri AC: Congenital absence of the portal vein: a complex disease with multiple manifestations and types of treatment. Eur J Pediatr Surg 21: 269-272, 2011.

84. Law YM, Mack CL, Sokol RJ, Rice M, Parsley L and Ivy D: Cardiopulmonary manifestations of portoovenous shunts from congenital absence of the portal vein: pulmonary hypertension and pulmonary vascular dilatation. Pediatr Transplant 15: E162-E168, 2011.

85. Uchida H, Sakamoto S, Shigeta T, et al: Living donor liver transplantation with renoportal anastomosis for a patient with congenital absence of the portal vein. Case Rep Surg 2012: 670289g, 2012.

86. Ogul H, Bayraktutan U, Yalcin A, Turan MI, Ozgokce M, Eren S and Kantarci M: Congenital absence of the portal vein in a patient with multiple vascular anomalies. Surg Radiol Anat 35: 529-534, 2013.

87. Banz V, Olliff S, Taniere P, Mayer D and Isaac J: Liver tumours in patients with Abernethy malformation. ANZ J Surg 81: 640-641, 2011.

88. Shinkai M, Ohhama Y, Nishi T, et al: Living related partial liver transplantation for hyperammonemia due to congenital absence of the portal vein. Transplant Proc 32: 2184, 2000.

89. Joyce AD and Howard ER: Rare congenital anomaly of the portal vein. Br J Surg 75: 1038-1039, 1988.

90. Bellah RD, Hayek J and Teele RL: Anomalous portal venous connection to the suprahepatic vena cava: sonographic demonstration. Pediatr Radiol 20: 115-117, 1989.

91. Marks C: Developmental basis of the portal venous system. Am J Surg 117: 671-681, 1969.

92. Moretti G, Staeffen J, Broustet A and Le Bras M: Congenital malformations associated with stenosis of the portal vein. Sem Hop 44: 893-897, 1968 (in French).

93. K Č S, Matsutani S, Maruyama H, et al: Portal-systemic encephalopathy in two patients without liver cirrhosis and portal hypertension. Hepatol Res 23: 122-129, 2002.